Ocugen, Inc. 2021 Q1 Form 10-Q Summary
Business Context and Reporting Period
Ocugen is a development-stage biopharmaceutical company focused on retinal gene therapies, biologic therapies, and the COVAXIN COVID-19 vaccine for the U.S. market. The filing covers the three months ended March 31, 2021, and was filed May 7, 2021. The company had no products approved for commercial sale and had not generated significant revenue.
- COVAXIN: Exclusive U.S. development, manufacturing, and commercialization rights under a February 2021 agreement with Bharat Biotech; Ocugen is entitled to 45% of profits generated in its territory.
- Retinal programs: OCU400 was planned for two U.S. Phase 1/2a trials in the second half of 2021; OCU410 and OCU200 were in preclinical development with Phase 1/2a trials targeted for 2022.
- Discontinued program: OCU300 development was discontinued in 2020 after an interim analysis indicated the Phase 3 trial was unlikely to meet its co-primary endpoints.
Financial Results and Key Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | Not applicable |
| Research and development expense | $2.9 million | $1.7 million | +$1.2 million |
| General and administrative expense | $4.2 million | $2.3 million | +$1.9 million |
| Total operating expenses | $7.1 million | $3.9 million | +$3.1 million |
| Net loss | $7.1 million | $3.9 million | +$3.1 million loss |
| Net loss per share | $0.04 | $0.07 | Improved due primarily to higher share count |
| Net cash used in operating activities | $5.3 million | $4.7 million | +$0.6 million use |
| Net cash provided by financing activities | $26.3 million | $0.5 million | +$25.8 million |
| Cash, cash equivalents, and restricted cash at period-end | $44.9 million | $3.3 million | +$41.6 million |
Gross margin and operating margin are not meaningful because the company reported no significant revenue and is operating at a loss. Accumulated deficit was $80.4 million at March 31, 2021.
Total debt had a carrying value of $2.1 million, consisting primarily of a $0.4 million PPP note and $1.7 million under the EB-5 Loan Agreement. The balance sheet also included $1.5 million of current and non-current operating lease obligations. Total assets were $53.8 million and total liabilities were $7.4 million.
Material Changes Versus the Prior Comparable Period
- R&D expense increased 74%, primarily because of higher OCU400, COVAXIN, and OCU200 development activity, professional fees, and stock-based compensation. These increases were partly offset by lower OCU300 costs.
- G&A expense increased 84%, including approximately $1.2 million of costs related to increasing authorized common shares and $0.5 million of additional stock-based compensation.
- Operating cash use increased to $5.3 million from $4.7 million as development spending increased.
- Financing activity increased substantially through a February registered direct offering, ATM sales, and option exercises. The company received $21.2 million of net proceeds from the registered direct offering and $4.8 million from ATM sales during the quarter.
- On March 18, 2021, Ocugen issued 54,745 Series B convertible preferred shares valued at approximately $5.0 million to Bharat Biotech as an advance payment for future COVAXIN supply.
- Common shares outstanding increased to approximately 188.2 million at March 31, 2021 from 184.0 million at December 31, 2020.
Guidance, Outlook, Risks, and Unusual Items
- Management expected 2021 R&D and G&A expenses to increase as the company evaluates the U.S. regulatory and commercialization path for COVAXIN and advances its retinal programs.
- Ocugen was awaiting additional Phase 3 data from Bharat Biotech before submitting a planned FDA Emergency Use Authorization application for COVAXIN. The filing stated that India’s COVID-19 surge was delaying the process.
- The company reported positive April 2021 interim COVAXIN efficacy results from Bharat Biotech’s Indian Phase 3 trial, but these results were not sufficient by themselves to establish U.S. authorization or commercialization.
- Key COVAXIN risks include FDA review and authorization uncertainty, dependence on Bharat Biotech for clinical data and vaccine supply, India’s temporary vaccine export restrictions, manufacturing capacity, changing variants, and delays in the Indian Phase 3 program.
- COVID-19 could delay clinical-trial enrollment, regulatory interactions, supply chains, employee availability, and access to capital.
- Management believed cash resources would fund operating and capital requirements through at least one year from issuance of the financial statements, while also expecting to raise additional capital. Failure to obtain financing could require delaying, reducing, or eliminating programs, pursuing strategic alternatives, or ceasing operations.
- Subsequent to quarter-end, the company issued an $0.8 million promissory note, shareholders approved increasing authorized common shares from 200 million to 295 million, and Ocugen completed a $100 million registered direct offering with net proceeds of $93.4 million.
- Remaining severance obligations from the OCU300-related workforce reduction were expected to total approximately $0.4 million during the remainder of 2021.
Important Facts for Investors to Verify
- Whether and when the FDA accepts and authorizes or rejects the planned COVAXIN EUA submission.
- Whether Bharat Biotech can provide the required clinical data and contracted vaccine quantities, particularly amid Indian export restrictions and supply constraints.
- The terms and fulfillment status of the expected COVAXIN supply agreement and the conditions for conversion of the Series B preferred stock.
- Cash burn, additional financing needs, dilution from future equity issuance, and the company’s ability to fund planned clinical programs.
- Progress, enrollment, and results of the planned OCU400 trials and the development timelines for OCU410 and OCU200.
- The extent to which the April 2021 financing and subsequent share authorization changed liquidity, capitalization, and potential dilution.
- Potential liabilities under the PPP note, EB-5 loan, leases, license agreements, and remaining severance commitments.